Targeted Therapy With Anaplastic Lymphoma Kinase Inhibitor (Alectinib) in Adolescent Metastatic Non–Small Cell Lung Carcinoma: 18F-NaF PET/CT in Response Evaluation. (October 2018)

• Record Type: Journal Article
• Authors: Usmani, Sharjeel; Marafi, Fahad; Rasheed, Rashid; Al Maraghy, Muneera; al Kandari, Fareeda
• Is Part Of: Clinical nuclear medicine. Volume 43:Number 10(2018)
• Publication Date: 2018-10
• Subjects: 18F-NaF PET/CT -- alectinib -- metastatic non–small cell lung carcinoma; Nuclear medicine -- Periodicals; Radioisotope scanning -- Periodicals; Nuclear Medicine -- Periodicals; 616.07575
• DOI: 10.1097/RLU.0000000000002220
• Languages: English
• ISSNs: 0363-9762

Abstract

Abstract : Abstract: Primary lung adenocarcinoma is extremely rare in the pediatric age group. We report an 18-year-old man with non–small cell lung carcinoma stage IV with brain and bone metastatic. Lung biopsy showed expression of PDL1 along with rearrangement of ALK gene at chromosome 2p23. However, neither mutation of ROS1 nor epidermal growth factor receptor overexpression was seen. Second-generation anaplastic lymphoma kinase (ALK) inhibitor (alectinib) is initiated as first line of treatment. After 8 months of treatment with alectinib, 18 F-NaF PET/CT demonstrated resolution of bone lesions. The present case show rapid and good response to alectinib in metastatic ALK-positive non–small cell lung carcinoma.